Advertisement

Topics

Intravitreal Ranibizumab in Retinal Pigment Epithelial Detachments

2014-07-23 21:13:21 | BioPortfolio

Summary

The purpose of this study is to demonstrate the efficacy of ranibizumab in patients with retinal pigment epithelial detachment secondary to age-related macular degeneration (AMD).

Description

Pigment epithelial detachments (PED) secondary to age-related macular degeneration (AMD) have been excluded from practically all study populations of ranibizumab studies so far. PED represents a special entity in AMD. As yet, no standard treatment has been established for this disease.The stimuli that induce PED are not very well known, but there is evidence suggesting that angiogenic factors such as vascular endothelial growth factor (VEGF) also play a role in the pathogenesis. Ranibizumab is an anti-VEGF antibody fragment that blocks VEGF activity in patients with neovascular AMD.

Study Design

Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Conditions

Pigment Epithelial Detachment

Intervention

intravitreal injection with ranibizumab

Location

Dept. of Ophthalmology, University of Bonn Medical Cneter
Bonn
Germany
53127

Status

Recruiting

Source

University Hospital, Bonn

Results (where available)

View Results

Links

Published on BioPortfolio: 2014-07-23T21:13:21-0400

Clinical Trials [1313 Associated Clinical Trials listed on BioPortfolio]

Ranibizumab for Treating Submacular Vascularized Pigment Epithelial Detachments

This is a multicenter, randomized, open-label study. 30 patients will be followed for a period of 12 months. All consented and enrolled patients will receive 0.5mg of intravitreal ranibi...

Aflibercept in Patients With Pigment Epithelial Detachments (PED)

Uncontrolled single site non randomized non interventional study to determine the safety and efficacy of intravitreal injections of Aflibercept in patients with recent vision loss due to r...

Intravitreal Bevacizumab for the Treatment of Central Serous Chorioretinopathy

Central serous chorioretinopathy (CSC) has been known since it was first described by Von Graefe and termed “idiopathic detachment of the macula” in 1866, is a well-characterized disor...

Intravitreal Injection of Ranibizumab Versus Sham Before Vitrectomy in Patients With Proliferative Diabetic Retinopathy

Certain percent of the eyes with proliferative diabetic retinopathymay require pars plana vitrectomy (PPV) due to vitreous haemorrhage, proliferative membrane, and tractional retinal detac...

Macular Edema Ranibizumab v. Intravitreal Anti-inflammatory Therapy Trial

The Macular Edema Ranibizumab v. Intravitreal anti-inflammatory Therapy (MERIT) Trial will compare the relative efficacy and safety of intravitreal methotrexate, intravitreal ranibizumab, ...

PubMed Articles [4819 Associated PubMed Articles listed on BioPortfolio]

Factors predicting 2-year treatment results of ranibizumab therapy for polypoidal choroidal vasculopathy in eyes with good baseline visual acuity.

This study aimed to explore predictors of long-term stabilization of polypoidal choroidal vasculopathy (PCV) lesions and vision in response to injection of intravitreal ranibizumab (IVR). The treated ...

Comment on: "Case report of a secondary macular hole closure after intravitreal bevacizumab therapy in a patient with retinal pigment epithelial detachment".

Response to comment on "Case report of a secondary macular hole closure after intravitreal bevacizumab therapy in a patient with retinal pigment epithelial detachment".

CHANGES IN PLASMA VASCULAR ENDOTHELIAL GROWTH FACTOR LEVEL AFTER INTRAVITREAL INJECTION OF BEVACIZUMAB, AFLIBERCEPT, OR RANIBIZUMAB FOR DIABETIC MACULAR EDEMA.

The aim of this study was to investigate the changes in plasma vascular endothelial growth factor (VEGF) level depending on the severity of diabetic retinopathy (DR) or diabetic macular edema (DME) an...

Safety of intravitreal injection of ranibizumab in early pregnancy: a series of three cases.

PurposeRanibizumab is used in the treatment of choroidal neovascularization (CNV). Although systemic exposure to ranibizumab is low after ocular administration, its mechanism of action must be regarde...

Medical and Biotech [MESH] Definitions

Separation of the inner layers of the retina (neural retina) from the pigment epithelium. Retinal detachment occurs more commonly in men than in women, in eyes with degenerative myopia, in aging and in aphakia. It may occur after an uncomplicated cataract extraction, but it is seen more often if vitreous humor has been lost during surgery. (Dorland, 27th ed; Newell, Ophthalmology: Principles and Concepts, 7th ed, p310-12).

The layer of pigment-containing epithelial cells in the RETINA; the CILIARY BODY; and the IRIS in the eye.

The single layer of pigment-containing epithelial cells in the RETINA, situated closely to the tips (outer segments) of the RETINAL PHOTORECEPTOR CELLS. These epithelial cells perform essential functions for the photoreceptor cells, such as in nutrient transport, phagocytosis of the shed photoreceptor membranes, and ensuring retinal attachment.

Detachment of the corpus vitreum (VITREOUS BODY) from its normal attachments, especially the retina, due to shrinkage from degenerative or inflammatory conditions, trauma, myopia, or senility.

The administration of substances into the VITREOUS BODY of the eye with a hypodermic syringe.

More From BioPortfolio on "Intravitreal Ranibizumab in Retinal Pigment Epithelial Detachments"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Ophthalmology
Ophthalmology is the branch of medicine that is devoted to the study and treatment of eye diseases. As well as mild visual defects correctable by lenses, ophthalmology is concerned with glaucoma, uveitis and other serious conditions affecting the eye, ...


Searches Linking to this Trial